The Priority Review

Tag

Stream

353 stories ยท page 23 of 30

Stories

  1. Clinical trials

    Ultragenyx posts results of Phase 3 DTX401 trial in Glycogen Storage Disease Type Ia

    The study enrolled 52 participants and completed primary data collection on February 20, 2024. It evaluated DTX401's ability to reduce or eliminate dependence on exogenous glucose replacement therapy and to improve glucose control quality.

  2. Clinical trials

    Hoffmann-La Roche posts results of Phase 3 obinutuzumab trial in childhood nephrotic syndrome

    The study, completed in September 2025, enrolled 85 participants aged 2-25 years and compared obinutuzumab with mycophenolate mofetil. Results were first posted on ClinicalTrials.gov on October 14, 2026.

  3. Clinical trials

    AbbVie presents Phase 3 AFFIRM data showing endoscopic remission with SKYRIZI in Crohn's disease

    The study reported that 35.8% of patients achieved endoscopic remission and 36.6% achieved ulcer-free endoscopy after subcutaneous SKYRIZI versus 10.2% and 10.2% with placebo. Safety findings through week 24 were consistent with the known safety profile of risankizumab, with no new safety signals.

  4. Policy

    CMS announces $2.3 million RHTP funding for Missouri rural healthcare

    The Trump Administration announced more than $2.3 million in Rural Health Transformation Program funding to Missouri, allocating $1.46 million for workforce recruitment and retention and $879,000 to launch a certified nurse midwife training program. The investment aims to expand childcare support for rural healthcare workers and increase maternal care access across the state.

  5. Clinical trials

    Huons Biopharma registers Phase 3 trial of HU-045 in glabellar lines

    The study was first posted on ClinicalTrials.gov on October 13, 2026. It plans to enroll 390 participants and compares HU-045 to Xeomin in adults with moderate or severe glabellar lines.

  6. Clinical trials

    Il-Yang Pharm. Co. registers Phase 3 trial of UROCOM-R1 plus UROCOM-R2

    The study plans to enroll 660 participants and is expected to start on November 9, 2026. It plans to compare the efficacy and safety of UROCOM-R1 plus UROCOM-R2 combination therapy with UROCOM-R1 or UROCOM-R2 monotherapy in patients with benign prostatic hyperplasia.

  7. Clinical trials

    Takeda registers Phase 3b trial of Zasocitinib in psoriatic arthritis

    Takeda plans to enroll 644 participants in a Phase 3b study of Zasocitinib (TAK-279) for active psoriatic arthritis, with a start date of January 11, 2027. The trial is expected to reach primary completion on April 18, 2030.

  8. Clinical trials

    GlaxoSmithKline registers Phase 3a study of recombinant zoster vaccine for cardiovascular events

    The study, led by GlaxoSmithKline, plans to enroll 16,390 participants and aims to evaluate the impact of RZV on major adverse cardiovascular events in adults 50 years and older with established cardiovascular disease or two or more risk factors. It is scheduled to begin on November 30, 2026, with primary completion expected on November 25, 2032.

  9. Clinical trials

    Lee's Pharmaceutical posts results of Phase 3 ciprofloxacin-fluocinolone otic solution trial

    The study enrolled 600 participants and was completed in October 2021. It evaluated the efficacy and safety of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution versus ciprofloxacin 0.3% alone in acute otitis externa.

  10. Clinical trials

    Good Molecules posts results of Phase 3 facial toner study

    The study enrolled 49 participants and evaluated a topical facial toner for improving skin lightness, texture and appearance in hyperpigmentation over 18 weeks. Results were first posted on ClinicalTrials.gov on October 13, 2026.

  11. Policy

    Paragon Labs expands leadership with former Apogee executives

    Paragon Labs announced that former senior leaders from Apogee Therapeutics have joined its team, led by Michael Henderson, M.D., to support clinical development of Paragon-discovered assets. The move follows Apogee's 2026 acquisition by AbbVie for over $10.9 billion.

  12. Policy

    Rona Therapeutics grants Roche exclusive worldwide license for ALK7-targeting RNAi therapy

    Rona Therapeutics announced it has granted Roche an exclusive worldwide license for its investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7). The agreement gives Rona up to $100 million in upfront and near-term milestone payments and up to $1.06 billion in potential development, regulatory and commercial milestone payments, plus tiered royalties on global net sales.